Currently, there are 88.93M common shares owned by the public and among those 38.73M shares have been available to trade.
The company’s stock has a 5-day price change of 6.31% and 363.63% over the past three months. TOI shares are trading 935.60% year to date (YTD), with the 12-month market performance up to 579.84% higher. It has a 12-month low price of $0.13 and touched a high of $3.50 over the same period. TOI has an average intraday trading volume of 1.26 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 9.99%, 36.44%, and 248.61% respectively.
Institutional ownership of Oncology Institute Inc (NASDAQ: TOI) shares accounts for 15.18% of the company’s 88.93M shares outstanding.
It has a market capitalization of $285.42M and a beta (3y monthly) value of 0.16. The earnings-per-share (ttm) stands at -$0.70. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.06% over the week and 7.88% over the month.
Earnings per share for the fiscal year are expected to increase by 46.48%, and 76.32% over the next financial year.
Looking at the support for the TOI, a number of firms have released research notes about the stock. BTIG Research stated their Buy rating for the stock in a research note on May 15, 2025, with the firm’s price target at $7. Jefferies coverage for the Oncology Institute Inc (TOI) stock in a research note released on February 26, 2024 offered a Buy rating with a price target of $2.50. Guggenheim was of a view on September 14, 2022 that the stock is Buy, while Jefferies gave the stock Buy rating on August 15, 2022, issuing a price target of $10.
